ChemoCentryx Receives European Medicines Agency PRIority

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis

MOUNTAIN VIEW, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI ), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRI ority ME dicines (PRIME) designation from the European Medicines Agency (EMA) for CCX168 for the treatment of ANCA-Associated Vasculitis, or AAV. As described by the EMA, PRIME aims to bring promising innovative medicines to patients faster by optimizing and supporting medicine development. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on clinical data.

ChemoCentryx had previously received orphan drug status in Europe for CCX168 for use in the two main forms of AAV, namely granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). In the newly conferred PRIME designation, EMA acknowledged that GPA and MPA are highly severe diseases, and that the safety profiles of the existing treatments are not optimal. Mortality at one year exceeds 15% and the predominant causes of early death are infection and active vasculitis. This, together with the severe toxicity and only partial efficacy of the currently used regimens indicate an unmet medical need for improved treatment options for patients with AAV.

Furthermore, the EMA confirmed its view that CCX168 provides a new mechanism of action for the treatment of GPA and MPA, and the potential of the product to significantly address the unmet medical need is supported by nonclinical and clinical data.

It was noted that nonclinical proof-of-principle has been demonstrated in two relevant disease models and the nonclinical safety profile appeared reassuring. The EMA also found that, while duration of the clinical exposure is currently limited, the magnitude of effect, measured using a valid endpoint of Birmingham Vasculitis Activity Score (BVAS) response, is promising and suggests steroid sparing potential.

“The EMA’s PRIME designation provides further validation of the potential of CCX168 to fulfill a high unmet medical need and change the current treatment paradigm in AAV,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “The use of steroid-containing standard treatment for AAV is thought to be the single biggest cause of premature death among these patients. Our goal with CCX168 is to eliminate or limit the use of steroids along with their deleterious side effects, while controlling the disease, and possibly, more rapidly. The PRIME designation will allow us to accelerate the regulatory review process, potentially allowing CCX168 to reach the market sooner than previously expected.”

Earlier this year, ChemoCentryx announced positive results from the Phase II CLEAR trial with CCX168 in patients with AAV. Chronic high dose steroid administration in the current standard of care (SOC) is associated with premature death and a spectrum of other harmful side effects in AAV therapy. The objective of the CLEAR trial was to replace chronic high dose steroids with CCX168 and to eliminate the safety issues associated with steroids, from the SOC regimen in AAV.

Results from the CLEAR trial showed that CCX168 has the potential to safely replace chronic high dose steroids, and patients receiving CCX168 showed improvement within four weeks of starting treatment based on BVAS, urinary albumin excretion, and health-related quality of life outcomes. Based on the results from the CLEAR trial, the Company plans to initiate the Phase III development program with CCX168 for the treatment of AAV by the end of 2016.

About EMA PRIME Designation PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on early clinical data. Through PRIME, the EMA offers early and proactive support to medicine developers to optimize the generation of robust data on a medicine’s benefits and risks and enable accelerated assessment of medicines applications. More information about PRIME can be found on the EMA website .

About ANCA-Associated Vasculitis Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or AAV, is a type of rare autoimmune inflammation caused by auto-antibodies. AAV encompasses granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis), microscopic polyangiitis (MPA), eosinophilic polyangiitis (formerly Churg-Strauss syndrome) and renal limited vasculitis.

AAV represents a severe and often fatal autoimmune disease that is characterized by inflammation that can destroy different organ systems. AAV is the lead indication in the Company's orphan and rare disease program which has the objective of eliminating chronic high dose steroids, which are associated with significant safety issues including death, from the standard of care (SOC) regimen in AAV and replacing steroids with CCX168.

AAV affects approximately 40,000 people in the U.S. (with approximately 4,000 new cases each year) and greater than 75,000 people in Europe (with at least 7,500 new cases each year), and is currently treated with courses of immuno-suppressants (cyclophosphamide or rituximab) combined with high dose steroid administration. Following initial treatment, up to 30 percent of patients relapse within six to 18 months, and approximately half of all patients will relapse within three to five years.

Current SOC for AAV is associated with significant safety issues. First year mortality is approximately 11 to 18 percent.  The single major cause of premature mortality is not disease-related adverse events, but rather infection that is thought largely to be a consequence of steroid administration.  Indeed, the multiple adverse effects of courses of steroid treatment (both initial courses and those that are repeated as a consequence of relapse) are major causes of both short-term and long-term disease and death. Such therapy related adverse events contribute significantly to patient care costs, as well as to the diminution of quality of life for patients.

By damaging the body's small blood vessels, AAV affects many organ systems, mostly the kidneys, eyes, lungs, sinuses and nerves. This damage is caused by the destructive activity of inflammatory leukocytes in the body, with neutrophils considered to be the terminal effector cell. In AAV, neutrophils are attracted to sites of vascular destruction as well as activated at those sites by the activity of the complement system product known as C5a and its receptor, C5aR, which is the target of CCX168.  By blocking the C5aR, CCX168 is thought to reduce vasculitis by reducing neutrophil activation, accumulation, and adhesion, as well as vascular permeability.

About CCX168 CCX168 is an orally-administered complement inhibitor, specifically targeting the C5a receptor (C5aR), which binds the complement fragment C5a. CCX168 is the lead drug candidate in the Company's orphan and rare disease program and is being developed for various autoimmune disorders including ANCA-associated vasculitis (AAV), atypical hemolytic uremic syndrome (aHUS) and immunoglobulin A nephropathy, or IgA nephropathy.

About ChemoCentryx ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing reduction and elimination of high-dose steroids, part of standard of care for AAV patients, without compromising efficacy or safety in clinical studies to date. CCX168 is also in Phase II studies for the treatment of atypical hemolytic uremic syndrome (aHUS) and immunoglobulin A nephropathy, or IgA nephropathy (IgAN). ChemoCentryx has licensed exclusive rights to Vifor Pharma to commercialize CCX168 in Europe and certain other markets outside of the U.S. and most of Asia.  CCX872, a CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. CCX140, a distinct CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvement in albuminuria in patients with diabetic nephropathy. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development, vercirnon (also known as Traficet-EN or CCX282) a specific CCR9 inhibitor for the treatment of inflammatory bowel disease, and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.

Forward-Looking Statements ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding whether CCX168 will be able to replace chronic high dose steroids and when and if CCX168 will obtain regulatory approval and be commercialized for the treatment of AAV. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC March 14, 2016 and its other reports which are available from the SEC's website ( www.sec.gov ) and on ChemoCentryx's website ( www.chemocentryx.com ) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. CCXI-G

Contacts: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer investor@chemocentryx.com Media: Denise Powell denise@redhousecomms.com 510.703.9491 Investors: Steve Klass Burns McClellan 212.213.0006 sklass@burnsmc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 41

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 98

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 81

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 13

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 0

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 161

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 88

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 14

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 111

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading

Top 5 Most Recently Viewed Articles

374Water Initiates Groundbreaking AFFF Destruction Project

Updated Category News Views 118

374Water's Innovative AFFF Destruction Initiative 374Water Inc. (NASDAQ: SCWO), a leading company in organic waste destruction technology, has embarked on a significant contract with the state of North Carolina. This initiative aims to tackle a critical environmental concern: the destruction of Aqueous Film-Forming Foam (AFFF). This contract represents a key milestone not...

Continue Reading
Beary Landscaping Expands with Strategic Acquisition of Sun Valley

Updated Category News Views 268

Exciting New Partnership in Landscaping Services Beary Landscaping has announced its recent acquisition of Sun Valley Landscape and Snow, marking a significant step in enhancing its capabilities within the Midwest's competitive landscape services sector. This strategic partnership aims to ensure that Beary can provide exceptional landscaping and snow removal services to...

Continue Reading
FiscalNote Unveils Custom AI Tariff Reports to Enhance Trade Decisions

Updated Category News Views 140

Introducing AI-Powered Tariff Impact Reports by FiscalNote FiscalNote Holdings, Inc. (NYSE: NOTE), a renowned provider of AI-driven policy and regulatory intelligence solutions, has rolled out a new feature: personalized tariff impact reports. These reports, integrated into the tariff tracking tool launched earlier this year, allow organizations to quickly assess how...

Continue Reading
Exciting Upcoming Episodes of UNSCRIPTED with Dino Rizzo

Updated Category News Views 156

Upcoming Episodes of UNSCRIPTED with Dino Rizzo The Association of Related Churches (ARC) is thrilled to announce the release of new episodes of UNSCRIPTED, hosted by Dino Rizzo. This innovative series showcases meaningful conversations with church leaders who are significantly influencing their communities. Engaging Conversations with Influential Leaders UNSCRIPTED is...

Continue Reading
NETSOL Technologies Powers New Leasing Operations in Indonesia

Updated Category News Views 165

NETSOL Technologies Launches Transcend Finance Platform NETSOL Technologies, Inc. (Nasdaq: NTWK), based in Encino, California, has made a significant advancement in the asset finance and leasing sphere with the launch of its Transcend Finance platform for a prominent Chinese leasing company. This event represents a milestone for the customer, marking their official...

Continue Reading